168 related articles for article (PubMed ID: 33283202)
1. Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis.
Zhang KW; Miao J; Mitchell JD; Alvarez-Cardona J; Tomasek K; Su YR; Gordon M; Cornell RF; Lenihan DJ
JACC CardioOncol; 2020 Mar; 2(1):56-66. PubMed ID: 33283202
[TBL] [Abstract][Full Text] [Related]
2. Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.
Swiger KJ; Friedman EA; Brittain EL; Tomasek KA; Huang S; Su YR; Sawyer DB; Lenihan DJ
Amyloid; 2016 Dec; 23(4):242-248. PubMed ID: 27809600
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
4. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
[TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of the Hepatocyte Growth Factor as a Predictor of Mortality in Patients Hospitalized With Acute Heart Failure Regardless of Ejection Fraction.
Pérez-Calvo JI; Morales-Rull JL; Gimeno-Orna JA; Lasierra-Díaz P; Josa-Laorden C; Puente-Lanzarote JJ; Bettencourt P; Pascual-Figal DA
Am J Cardiol; 2016 Aug; 118(4):543-9. PubMed ID: 27338207
[TBL] [Abstract][Full Text] [Related]
7. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
[TBL] [Abstract][Full Text] [Related]
8. Myocardial contraction fraction derived from cardiovascular magnetic resonance cine images-reference values and performance in patients with heart failure and left ventricular hypertrophy.
Arenja N; Fritz T; Andre F; Riffel JH; Aus dem Siepen F; Ochs M; Paffhausen J; Hegenbart U; Schönland S; Müller-Hennessen M; Giannitsis E; Kristen AV; Katus HA; Friedrich MG; Buss SJ
Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1414-1422. PubMed ID: 28165128
[TBL] [Abstract][Full Text] [Related]
9. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
[TBL] [Abstract][Full Text] [Related]
10. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
11. Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient.
Vergaro G; Castiglione V; Poletti R; Buda G; Pucci A; Musetti V; Genovesi D; Aimo A; Passino C; Emdin M
JACC Case Rep; 2021 Mar; 3(3):450-454. PubMed ID: 34317556
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.
Castano A; Haq M; Narotsky DL; Goldsmith J; Weinberg RL; Morgenstern R; Pozniakoff T; Ruberg FL; Miller EJ; Berk JL; Dispenzieri A; Grogan M; Johnson G; Bokhari S; Maurer MS
JAMA Cardiol; 2016 Nov; 1(8):880-889. PubMed ID: 27557400
[TBL] [Abstract][Full Text] [Related]
13. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis.
Perlini S; Salinaro F; Musca F; Mussinelli R; Boldrini M; Raimondi A; Milani P; Foli A; Cappelli F; Perfetto F; Palladini G; Rapezzi C; Merlini G
J Hypertens; 2014 May; 32(5):1121-31; discussion 1131. PubMed ID: 24509117
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
16. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial.
Hijazi Z; Verdecchia P; Oldgren J; Andersson U; Reboldi G; Di Pasquale G; Mazzotta G; Angeli F; Eikelboom JW; Ezekowitz MD; Connolly SJ; Yusuf S; Wallentin L
J Am Heart Assoc; 2019 Jan; 8(2):e010107. PubMed ID: 30651032
[TBL] [Abstract][Full Text] [Related]
17. A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy.
Zhang KW; Zhang R; Deych E; Stockerl-Goldstein KE; Gorcsan J; Lenihan DJ
Am Heart J; 2021 Feb; 232():137-145. PubMed ID: 33212046
[TBL] [Abstract][Full Text] [Related]
18. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
[TBL] [Abstract][Full Text] [Related]
19. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis.
Takashio S; Yamamuro M; Izumiya Y; Hirakawa K; Marume K; Yamamoto M; Ueda M; Yamashita T; Ishibashi-Ueda H; Yasuda S; Ogawa H; Ando Y; Anzai T; Tsujita K
ESC Heart Fail; 2018 Feb; 5(1):27-35. PubMed ID: 28869340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
